1. Home
  2. ECOR vs GIFT Comparison

ECOR vs GIFT Comparison

Compare ECOR & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECOR
  • GIFT
  • Stock Information
  • Founded
  • ECOR 2005
  • GIFT 1999
  • Country
  • ECOR United States
  • GIFT United States
  • Employees
  • ECOR N/A
  • GIFT N/A
  • Industry
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • GIFT Catalog/Specialty Distribution
  • Sector
  • ECOR Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • ECOR Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • ECOR 37.1M
  • GIFT 33.9M
  • IPO Year
  • ECOR 2018
  • GIFT N/A
  • Fundamental
  • Price
  • ECOR $4.96
  • GIFT $1.07
  • Analyst Decision
  • ECOR Strong Buy
  • GIFT Strong Buy
  • Analyst Count
  • ECOR 2
  • GIFT 1
  • Target Price
  • ECOR $25.50
  • GIFT $4.00
  • AVG Volume (30 Days)
  • ECOR 99.3K
  • GIFT 28.1K
  • Earning Date
  • ECOR 08-06-2025
  • GIFT 08-13-2025
  • Dividend Yield
  • ECOR N/A
  • GIFT N/A
  • EPS Growth
  • ECOR N/A
  • GIFT N/A
  • EPS
  • ECOR N/A
  • GIFT N/A
  • Revenue
  • ECOR $27,700,000.00
  • GIFT $90,569,384.00
  • Revenue This Year
  • ECOR $24.48
  • GIFT $5.90
  • Revenue Next Year
  • ECOR $44.35
  • GIFT $13.45
  • P/E Ratio
  • ECOR N/A
  • GIFT N/A
  • Revenue Growth
  • ECOR 30.16
  • GIFT 8.55
  • 52 Week Low
  • ECOR $4.16
  • GIFT $0.82
  • 52 Week High
  • ECOR $19.49
  • GIFT $3.93
  • Technical
  • Relative Strength Index (RSI)
  • ECOR 41.18
  • GIFT 49.23
  • Support Level
  • ECOR $4.74
  • GIFT $1.02
  • Resistance Level
  • ECOR $5.32
  • GIFT $1.15
  • Average True Range (ATR)
  • ECOR 0.34
  • GIFT 0.07
  • MACD
  • ECOR 0.00
  • GIFT 0.01
  • Stochastic Oscillator
  • ECOR 22.22
  • GIFT 23.70

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: